AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...

Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...

"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

AstraZeneca said its Imfinzi drug when used with chemotherapy had shown “statistically significant and clinically meaningful improvement” in survival in resectable early-stage gastric and ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...